In this edition of IJS new therapeutic opportunities are highlighted. First, a metanalysis of all the trials so far of tenectaplase versus alteplase for acute stroke thrombolysis using individual patient data, clearly tenectaplase has great promise as a more effective, and safer form of thrombolysis but phase III, level 1 evidence is required, such as may be generated from the ongoing TASTE trial. Second, interesting data from the embolic stroke of unknown embolic stroke of undetermined source (ESUS) global registry provides additional background for the opportunity for new interventions such as the novel oral anticoagulants (NOACS). They found about 1/6 of all ischemic strokes were in the ESUS category and that they generally were younger, had milder deficits, and were usually treated with antiplatelet agents. This should prime us for the results of such trials as RE-SPECT ESUS, and NAVIGATE ESUS.
Those who have been following the INTERACT studies will be interested to see that a post hoc analysis of the entire data set for the use of heparin prophylactically for thromboembolic events within seven days of ICH had a poor outcome, a result which should influence clinical practice. Finally, our fascinating series profiling young stroke investigators from around the globe continues with the spotlight on Dar Dowlatshahi from Canada.
We hope to see you at the coming World Stroke Congress!
